Superior Sulcus Tumors Research Articles

8157 Hypercalcemia To Hypocalcemia In Three Days: The Importance Of Asking The Questions

Abstract Disclosure: P. Kachhadia: None. K. Patel: None. S. Khan: None. A. Abu Limon: None. S. Aldasouqi: None. F. Akanbi: None. Z. Ul Abideen: None. Introduction: Severe hypercalcemia needing inpatient hospitalization requires very thorough history taking in order to determine etiology and treatment plan. Causes differ drastically, and misdiagnosis or mistreatment can be life threatening. Here, we present a case of symptomatic hypercalcemia secondary to milk-alkali syndrome that was treated promptly after admission with IV zoledronic acid, leading to severe symptomatic hypocalcemia and prolonged hospitalization. Case presentation: Patient is a 68 year old female with a PMH of breast cancer, osteoporosis and hiatal hernia who presented to the emergency department for fatigue, constipation and lightheadedness. On evaluation, she was found to have a creatinine of 1.54 (0.6-1.1 mg/dL), eGFR 36 (>90 mL/min/1.73 m²), Ca 18.48 (8.6-10.2 mg/dL), albumin 4.7 (3.4-5.4 g/dL), Mg1.4 (1.7-2.2 mg/dL), 25-OHD 18 (30-100), 1,25-Dihydroxy Vitamin D 7.4 (18-78 pg/mL), PTH 11.2 (15-65 pg/mL), phosphorus level 2.4 (2.5-4.5mg/dL), TSH 2.01 (0.4-4.0 mIU/L). SPEP and PTHrP were unremarkable. Due to history of prior breast cancer, imaging was done and CT showed new possible RUL pancoast tumor with RUL spiculated opacity. Patient was started on IV fluids and subsequently received IV zoledronic acid due to concern for severe hypercalcemia secondary to malignancy. By day 3 of treatment, patient's calcium decreased severely, down to a corrected calcium level of 6.4 (8.6-10.2 mg/dL). It was upon further investigation and discussion with the patient that we discovered the patient had received subcutaneous denosumab for her osteoporosis three weeks prior to admission. In addition, she was taking six tums daily (total 1 month duration) for symptoms of dyspepsia secondary her hiatal hernia. The patient’s severe hypocalcemia was treated with high dose oral calcium carbonate and vitamin D along with IV calcium gluconate. Magnesium was replaced daily. Through daily replacement, patient was kept in the hospital for a total of 10 days duration before her calcium levels were deemed safe for return home. Discussion: Hypercalcemia is a common cause of hospitalization worldwide. Testing should be comprehensive and history taking should be thorough to help navigate treatment plans. Bisphosphonates are indicated for hypercalcemia of malignancy, and its use otherwise may be the cause of severe hypocalcemia if not used in the right setting. In our case, the patient’s hypocalcemia was multifactorial from prior denosumab use and then subsequent zoledronic acid use. Additional risk factors included low vitamin D counts and disruption of high amounts of over the counter tums after being admitted to the hospital. Anchoring bias also led clinicians to believe that the hypercalcemia was secondary to malignancy. Consequently, this led to a prolonged 10 day hospitalization for persistently low calcium levels. Presentation: 6/1/2024

A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement

BackgroundDurvalumab after chemoradiation (PACIFIC regimen) provides favorable treatment outcomes for unresectable stage III non-small cell lung cancer (NSCLC). The feasibility of salvage surgery after the PACIFIC regimen has been reported in some studies; however, its efficacy remains unclear. We herein present the first case of salvage surgery after the PACIFIC regimen for a superior sulcus tumor with N3 involvement, in which a pathological complete response was achieved.Case presentationA 53-year-old man with a left superior sulcus tumor with N3 (# 1L, #4R) involvement (adenocarcinoma, clinical T3N3M0/IIIC) underwent concurrent chemoradiotherapy (2 cycles of cisplatin plus vinorelbine with 60 Gy radiotherapy) followed by durvalumab treatment for 1 year at a previous hospital. The PACIFIC regimen provided a significant primary tumor shrinkage (diameter 3.1 cm to 0.5 cm) with the disappearance of 18F-fluorodeoxyglucose uptake in all nodes. Six months after the end of the PACIFIC regimen, only the primary tumor showed enlargement (diameter 0.5 cm to 2.0 cm). Accordingly, local tumor recurrence was suspected. Salvage surgery (left upper lobectomy with combined chest wall resection [1st to 4th rib]) was performed. The histological examination revealed no viable tumor cells (ypT0N0M0). At 7 months after salvage surgery, the patient remains alive with no signs of tumor recurrence.ConclusionsThe present case suggests that salvage surgery may be feasible after the PACIFIC regimen for superior sulcus tumors. A long-term follow-up is essential to determine the efficacy of salvage surgery.

Carbon Ion Beam Radiation Therapy as Part of a Trimodal Therapy for Non-small Cell Superior Sulcus Tumors: The INKA Study

Purpose/ObjectiveSuperior sulcus tumors are frequently treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery in a trimodal approach. The INKA study evaluated the replacement of photon irradiation by carbon ion radiotherapy (C12-RT) in this regimen. Material/methodsThe prospective INKA-study included patients with locally advanced non-small cell superior sulcus tumors (<cN3 cM0). Patients received 2 cycles of cisplatin and vinorelbine as per local standard. During the second cycle, 39Gy(RBE) of hypofractionated C12-RT in 13 fractions were applied. Surgery following an FDG-PET/CT restaging was performed 2 weeks later. The primary endpoint was feasibility and safety measured by the incidence of CTCAE (v4.0) grade 3/4 toxicity and/or discontinuation due to any reason. Secondary endpoints included the morphological (RECIST 1.0), metabolic (PERCIST 1.0) and histopathological response after nCRT as well as Quality of Life measurement (QLQ-C30/LC13). ResultsBetween 2015 and 2020, 14 patients were included and received nCRT. No grade 3/4 toxicity occurred with no discontinuation due to toxicity. Before surgery, 8 patients (57%) showed a partial response on CT scan. Thirteen patients showed a metabolic response (mCR=1, mPR=12). Three patients were judged as inoperable after nCRT (21%). In patients with resection, a pathological CR was seen in 2 patients (19%) and near-complete remission (<10% vital tumor cells) in 6 patients (55%). Pain score was more than halved compared to baseline (mean: 69.2±26.2 vs. 30.6 ± 29.1; p=0.005) after completion of nCRT and before surgery. ConclusionThe INKA trial is the first study to evaluate nCRT with C12-RT and showed excellent response, low toxicity and rapid pain relief.

Utility of transmanubrial osteomuscular sparing approach and its modification in vascular surgery: a case series study of surgeries related to subclavian artery

BackgroundThe operative field in subclavian vessel surgery is limited by thoracic inlet and outlet structures. Although endovascular therapy for the subclavian artery could be an option, open repair management is occasionally required in cases of large aneurysms, infectious vasculopathy, and trauma. The transmanubrial osteomuscular sparing approach, commonly used in thoracic surgery area to resect superior sulcus tumors, is a simple and safe procedure providing an excellent view of the operative field. Herein, we present three cases that underwent open repair of the subclavian artery using the transmanubrial osteomuscular sparing approach, and we also highlight the utility of the technique along with the procedural details.Case presentationCase 1: A 54-year-old man presented with a true aneurysm of the proximal portion of the right subclavian artery. The aneurysm measured 50 × 80 mm and compressed the right lung and trachea. We performed an aneurysm resection and a right subclavian artery reconstruction via the transmanubrial osteomuscular sparing approach under cardiopulmonary bypass support.Case 2: A 72-year-old man who presented with an abscess that formed around the left subclavian artery due to an unremoved guidewire during thoracic endovascular aortic repair for an aortic arch aneurysm in another hospital. After the antibiotics administration, debridement and axillary-axillary bypass were performed, and the guidewire was removed via a transmanubrial osteomuscular sparing approach with a use of cardiopulmonary bypass.Case 3: A 60-year-old man presented with misplacement of an indwelling dialysis catheter inserted for acute renal failure and hyperkalemia. The catheter was placed through the right neck, but had penetrated the right internal jugular vein and was misplaced from the right subclavian artery into the proximal aortic arch. Emergently, we removed the catheter using the transmanubrial osteomuscular sparing approach.ConclusionsThe transmanubrial osteomuscular sparing approach to the subclavian artery provides an excellent view and a wide surgical field, even in different pathological situations. This is a simple, safe, and highly useful procedure and could be the standard approach for subclavian artery surgeries.

Pancoast-Tobias Syndrome Due to a High-Grade Fibrous Histiocytoma: A Case Report

Bronchogenic cancers account for an overwhelming majority of all malignancies responsible for Pancoast syndrome. However, the spectrum of non-bronchogenic malignant causes is broad and although less frequent, they are characterized by late diagnosis at advanced disease stage with a poor prognosis. The clinical presentation of Pancoast tumors can be polymorphic based on the etiology and anatomic extent, leading to considerable delays in the request of appropriate investigative techniques. Chest radiography may be helpful in first-line imaging but the cross-sectional modalities are more sensitive for diagnosis, staging and follow-up of treatment. Early reporting of symptoms and increased clinical vigilance could lead to an early diagnosis and improved 5-year survival. We report the case of a 40-year-old male with worsening left shoulder and arm pain over the course of a few months and a left neck swelling.

Trousseau Syndrome with the MR Three-territory Sign as the Initial Manifestation of an Occult Pancoast Tumor: A Case Report (P8-5.026)

Trousseau Syndrome with the MR Three-territory Sign as the Initial Manifestation of an Occult Pancoast Tumor: A Case Report (P8-5.026)

Pancoast Syndrome Due to Metastatic Hepatocellular Carcinoma

Pancoast tumors are aggressive and locally invasive apical lung cancers that often compress and infiltrate adjacent structures including the brachial plexus, stellate ganglion, ribs, and vertebral bodies. Symptoms of Pancoast tumors include Pancoast Syndrome, characterized by Horner Syndrome and pain and weakness of the ipsilateral upper extremity. Pancoast tumors by definition are primary lung cancer and are nearly always non-small cell lung cancer (NSCLC). There are rare case reports of metastatic non-pulmonary malignancies forming apical lung tumors mimicking Pancoast tumors and causing Pancoast Syndrome. Here, we present a case of a 66-year-old male with a history of unresectable hepatocellular carcinoma (HCC) who presented with one year of progressive left wrist and forearm pain and hand weakness and was found on cross-sectional imaging to have a left upper lobe lung mass invading the T1 and T2 vertebral bodies. Pathology showed very poorly differentiated carcinoma that required specialized testing to achieve diagnostic clarity. The tumor was positive for albumin mRNA, which aided in confirming the lung mass as metastatic HCC. This case highlights a rare incidence of Pancoast Syndrome due to metastatic HCC and emphasizes the importance of considering this diagnosis as an etiology of left upper extremity pain in a patient with previously diagnosed malignancy. This case also demonstrates the utility of albumin mRNA in-situ hybridization as an additional tool in identifying metastatic HCC and reviews general principles of symptomatic management of Pancoast Syndrome.

Diagnostic importance of Bone scan and SPECT-CT in atypical cases of CRPS presenting to pain clinic: A case report

Establishing a diagnosis of complex regional pain syndrome (CRPS) is challenging and often requires a multidisciplinary approach. Skeletal scintigraphy (bone scan) can be helpful in diagnosing and staging CRPS. Presented here is an interesting case of the right upper extremity and pectoral region pain, which upon evaluation with skeletal scintigraphy and single photon emission computed tomography with computed tomography (SPECT-CT) turned out to be Pancoast tumor.

Pancoast tumors

Pancoast tumors

Shoulder and arm pain: A “red herring” chief complaint in a smoker diagnosed with Pancoast-Tobías syndrome

Introduction: A Pancoast tumor is a rare apical lung cancer that can lead to a constellation of signs and symptoms known as Pancoast-Tobías syndrome, which involves ipsilateral shoulder and arm pain, Horner’s syndrome, and atrophy of the intrinsic hand muscles. As a Pancoast tumor progresses, it first invades the brachial plexus and causes unrelenting shoulder and arm pain in the C8-T2 nerve distributions. However, when evaluating this presenting symptom, it is often considered benign, especially in aging patients. Consequently, Pancoast-Tobías syndrome is easily misdiagnosed or delayed in diagnosis, resulting in poor prognosis, particularly for patients with advanced disease. Case Report: We present the case of an elderly Afro-Caribbean woman with a 24-pack-year smoking history who presented with unrelenting pain to the right shoulder and arm for two months. During that time, she visited multiple family physicians. Onset of pain coincided with a wasp sting that was complicated by a large local reaction. Despite clinical resolution of the inflammatory reaction, the pain persisted even with multi-modal oral analgesics. Detailed physical examination later revealed ipsilateral atrophy of the intrinsic hand muscles and focal chest findings concerning for an underlying consolidative lung process. This prompted diagnostic chest imaging, which identified a right-sided Pancoast tumor aggressively invading adjacent structures. She soon developed Horner’s syndrome, resulting in clinicoradiologic confirmation of Pancoast-Tobías syndrome. Conclusion: It is important to consider Pancoast-Tobías syndrome as an important differential of unrelenting shoulder and arm pain, even in the absence of pulmonary symptoms, in patients with risk factors for lung cancer, such as chronic smokers.

Discussion to: Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management.

Discussion to: Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management.

Superior Sulcus Tumors Invading the Spine: Multimodal Treatment Outcomes From the Preimmunotherapy Era

IntroductionCurative-intent treatment of superior sulcus tumors (SSTs) of the lung invading the spine presents considerable challenges. We retrospectively studied outcomes in a single center, uniformly staged patient cohort treated with induction concurrent chemoradiotherapy followed by surgical resection (trimodality therapy). MethodsAn institutional surgical database from the period between 2002 and 2021 was accessed to identify SSTs in which the resection included removal of at least part of the vertebral body. All patients were staged using fluorodeoxyglucose positron emission tomography (/computed tomography), computed tomography scan of the chest/upper abdomen, and brain imaging. Surgical morbidity was assessed using the Clavien-Dindo classification. Overall and disease-free survival were calculated using the Kaplan-Meier method. ResultsA total of 18 patients were included: 8 complete and 10 partial vertebrectomies were performed, with six of the eight complete vertebrectomies involving two vertebral levels, resulting in Complete surgical resection (R0) in 94%. Nine patients had a 1-day procedure, and nine were staged over 2 days. The median follow-up was 30 months (interquartile range 11–57). The 90-day postoperative morbidity was 44% (grade III/IV), with no 90-day surgery–related mortality. There were 83% who had a major pathologic response, associated with improved survival (p = 0.044). The 5-year overall and disease-free survival were 55% and 40%, respectively. Disease progression occurred in 10 patients, comprising locoregional recurrences in two and distant metastases in eight patients. ConclusionsMultimodality treatment in selected patients with a superior sulcus tumor invading the spine is safe and results in good survival. Such patients should be referred to expert centers. Future research should focus on improving distant control (e.g. [neo]adjuvant immunotherapy).

Apical pulmonary hydatid cyst: About a rare cause of Pancoast syndrome

Objectives: Our purpose is to illustrate the radiological aspects of an apical hydatid cyst as a rare cause of Pancoast Tobias syndrome. Material: We report the case of a 35 years-old man, who was admitted to our department with a Pancoast tobias syndrome. Results: The patient presented to our department with a history of shoulder and right chest pain radiating downward toward the ulnar side of his homolateral arm. He also reported hemoptysis and hydatidemesis (hydatid cysts and membranes in the vomitus). Radiological investigations suggested the diagnosis of hydatid cyst of the left lung apex which was confirmed by surgical excision and pathological examination of the lesion. This case highlights an uncommon etiology of Pancoast syndrome which might mislead physicians in their practice. Conclusion: In conclusion, a primary hydatid cyst should be considered in the differential diagnosis of Pancoast's syndrome especially in endemic regions. Unlike Pancoast tumors, this benign lesion has a very favourable prognosis and good surgical results.

Superior sulcus non–small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management

ObjectiveDespite neoadjuvant chemoradiotherapy, Pancoast tumors still present surgical and oncologic challenges. To optimize outcomes, we used a multidisciplinary care paradigm with medical and radiation oncology, and involvement of spine neurosurgery for most T3 and all T4 tumors. Spine neurosurgery permitted resection of transverse process for T3 and vertebral body resection for T4 tumors. MethodsRetrospective analysis of single institution, prospective database of patients undergoing resection for cT3 4M0 Pancoast tumors. Patients were grouped as cT3 with combined resection with spine neurosurgery (T3 Neuro), cT3 without spine neurosurgery (T3 NoNeuro), and cT4. Overall survival, progression-free survival were analyzed by Kaplan-Meier and compared between groups using log-rank test. Cumulative incidence of local-regional and distant recurrence were compared using Gray test. P value <.05 was considered significant. ResultsFrom 2000 to 2021, 155 patients underwent surgery: median age was 58 years, and 81 were (52%) men. Most patients received neoadjuvant platinum-based neoadjuvant chemoradiotherapy (n = 127 [82%]). Operations were 48 cT3 Neuro, 41 cT3 NoNeuro, 66 cT4. R0 resection was achieved in 49 (94%) cT3 NoNeuro, 35 (85%) cT3 Neuro, and 57 (86%) cT4 patients (P = .4). Complete or major pathologic response occurred in 71 (55%) patients. Lower local-regional cumulative incidence was seen in cT3 Neuro versus cT3 NoNeuro (P = .05) and after major pathologic response. Overall survival and progression-free survival were associated with complete response, pathologic stage, and nodal status but not cT category. ConclusionsThis treatment paradigm was associated with a high frequency of R0 resection, complete response, and major pathologic response. cT3 and cT4 tumors had similar outcomes. Novel therapies are needed to improve complete response.

Surgical Approaches to Pancoast Tumors.

Pancoast tumors, also defined as superior sulcus tumors, still represent a complex clinical condition requiring high technical surgical skills within more articulated multimodality treatment. The morbidity and mortality rates after Pancoast tumor treatments range from 10 to 55% and 0 to 7%, respectively, and the 5-year survival rate has significantly improved in recent years thanks to the advancement of treatments. Although a multimodality approach combining chemotherapy, radiotherapy, and surgery allows for radical resection and effective local control in the vast majority of patients, many patients cannot receive surgical resection or complete the whole programmed therapeutic regimen. Systemic relapse, particularly cerebral recurrence, still poses a significant issue in this cohort of patients. Surgical resection still plays a pivotal role within the multimodality approach. Here, we focus on surgical approaches to both anterior and posterior Pancoast tumors: the anterior transclavicular approach (Dartevelle); the anterior transmanubrial approach (Grunenwald-Spaggiari); the anterior trap-door approach (Masaoka, Nomori); the posterior approach (Shaw-Paulson); the hemiclamshell approach; and hybrid approaches. Global clinical condition, tumor histology, and long-term perspectives should always be taken into consideration when embarking on such a demanding oncologic scenario.

PANCOAST TUMOR PRESENTING WITH HORNER SYNDROME: A CASE REPORT

Case Report: A 50-year-old man was referred to Dr. Moewardi General Hospital with history of right chest pain that radiate to the right back and hand for 2 months. His complaint did not improve with medication and physical therapy. On physical examination we observed multiple nodules on the right axilla, scapula, and colli region. Neurological examination revealed right sided partial ptosis, anisocoria, ipsilateral weakness, and ipsilateral allodynia, and anhidrosis T1 dermatome. CT-scan showed a right lung mass in the superior lobe of the apical segment. The diagnosis of Horner syndrome is then established caused by multiple lymphadenopathies. His symptoms then relieved after lymphadenectomy. Conclusion: Horner syndrome, characterized by ipsilateral pupillary anisocoria, ptosis and anhidrosis, is one of the complications of Pancoast tumor invasion to the sympathetic nervous system in the C8, T1, and T2 nerve territory.

Superior Pulmonary Sulcus (Pancoast) Tumor: Historical Aspect, Terms and Definitions

В статье описываются этапы формирования современных представлений об опухоли Панкоста (Pancoast tumor), клинически проявляющейся болевым синдромом и глазными расстройствами. Утвердившийся эпоним опухоли и синдрома включает имя американского рентгенолога Г.К. Панкоста (H.K. Pancoast), подробно описавшего клинико-рентгенологическую семиотику опухоли и давшего ей название «опухоль верхней легочной борозды» ("superior pulmonary sulcus tumor", англ.) в 1924 и 1936 годах. Несмотря на почти 100 лет, прошедших с этого времени, правомочность названия, анатомический аспект, органное происхождение опухоли, ее гистогенез и особенности клинического течения являются предметом дискуссии до настоящего времени. Исторический приоритет описания опухоли и синдрома принадлежит английского хирургу Э.С. Хэйру (E.S. Hare), однако его открытие стало широко известным уже после того, как возник эпоним, связанный с именем Г.К. Панкоста. До настоящего времени в научных публикациях встречаются заблуждения относительно концепции Панкоста об этой опухоли и ее названия – «опухоль верхней легочной борозды».

Case Report with a Review of Literature: Pancoast Syndrome—A Rare Presentation of Metastatic Hepatocellular Carcinoma

AbstractSuperior sulcus tumors, also known as Pancoast tumors, present in a distinctive way with Horner's syndrome (ptosis, miosis, and anhidrosis), hand weakness brought on by the atrophy of the intrinsic hand muscles, and excruciating pain along the medial aspect of the arm. (1) Primary lung cancers constitute a majority of Pancoast tumors, but Pancoast syndrome can be multifactorial. (2) Here, we present a case of 62-year-old male who presented with right shoulder pain and weakness for 2 months. Clinically, he had a supraclavicular mass with atrophy of the intrinsic muscles of the hand and sensory-motor weakness. Computed tomography showed a mass lesion in the supraclavicular fossa with the erosion of the T1 vertebra and first rib, mimicking carcinoma right upper lobe. However, the biopsy from the mass was suggestive of metastasis from hepatocellular carcinoma (HCC). Our case report identifies HCC as a rare differential for Pancoast syndrome and highlights the unique metastatic presentation.

CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.

8514 Background: A multicenter, single-arm, confirmatory trial (CRES3T) was conducted to investigate the efficacy and safety of S-1 plus cisplatin and concurrent radical-dose thoracic radiotherapy (TRT) followed by surgery in patients with superior sulcus tumor (SST). To date, no clinical trials on radical-dose TRT in the induction setting for SST have been conducted. Methods: SST was defined as a tumor that directly invades the chest wall including the first rib or more cephalad, subclavian artery, or subclavian vein according to CT or MRI scans. Eligible patients were 20 to 75 years old and had pathologically proven non-small cell lung cancer, performance status of 0–1, and no history of prior treatment. The patients received induction therapy consisting of three cycles of S-1 plus cisplatin with concurrent TRT (66 Gy in 33 fractions) followed by surgery. S-1 was administered orally at 40 mg/m2 twice per day, on days 1–14 along with an intravenous infusion of cisplatin (60 mg/m2) on day 1. The treatment cycles were repeated every four weeks. The primary endpoint was the 3-year overall survival (OS) rate, and key secondary endpoints included progression-free survival (PFS) rate, objective response rate (ORR), pathological complete remission (pCR) rate, and toxicity. Results: Between June 2014 and March 2019, 61 patients registered and received induction therapy. Pathological diagnoses were 30 adenocarcinoma, 20 squamous cell carcinoma, and 11 others. Radiologically diagnosed tumor invasion sites were the chest wall (n=57), subclavian artery (n=18), and subclavian vein (n=10). One patient with distant metastasis that manifested after starting induction therapy was removed from this study. Forty-nine patients underwent lobectomy and resection of the involved sites. The complete resection rate was 98% (48/49). Median follow-up time was 54 months. The 3-year OS and PFS rates were 73% (95% CI: 60–83%) and 53% (95% CI: 40–65%), respectively. The ORR and pCR rate were 42% (25/60, 95% CI: 29–54%) and 33% (16/49, 95% CI: 20–46%), respectively. Grade (G) 3 or 4 toxicities during induction therapy included neutropenia (28%), anemia (13%), thrombocytopenia (5%), and hyponatremia (8%). Two (3%) cases of pneumonia resulted in death. G3 surgical complications such as supraventricular arrhythmia, chylothorax, pleural effusion, pneumonia, mediastinitis, wound infection, and arm neuropathy developed in one (2%) patient each. One (2%) cardiac arrest on postoperative day 3 resulted in death. Conclusions: CRES3T demonstrated that induction therapy using S-1 plus cisplatin and concurrent radical-dose TRT followed by surgery was safe and effective in treating SST. Therefore, this strategy is potentially a new standard treatment for SST. (UMIN: 000014386, jRCT: s031180401.). Clinical trial information: UMIN000014386 .

Burkitt’s Lymphoma Presenting as Pancoast Syndrome: A Rare Clinical Entity

This article describes a rare clinical presentation of Burkitt’s lymphoma, an aggressive malignancy that presented as an anterior mediastinal mass causing Pancoast syndrome in a 39-year-old pregnant woman. The patient presented with respiratory distress, right upper limb monoparesis, significant weight loss, and multiple bilateral axillary and cervical lymphadenopathies. Blood tests revealed non-regenerative anemia and thrombocytopenia, and a cervico-thoraco-abdomino-pelvic scan showed a lobulated, tissue-dense mass with supraclavicular extension, located at the right paramediastinal apex. The bone marrow biopsy showed disseminated Burkitt lymphoma. The article highlights the diverse clinical manifestations of Burkitt lymphoma and discusses its clinical variants, diagnostic techniques, and symptoms. Early diagnosis and treatment are crucial for a favorable outcome.